argenx's (ARGX) Outperform Rating Reiterated at William Blair

argenx (NASDAQ:ARGX - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at William Blair in a research note issued to investors on Friday,RTT News reports. William Blair also issued estimates for argenx's FY2026 earnings at $26.61 EPS, FY2027 earnings at $28.62 EPS and FY2028 earnings at $40.92 EPS.

ARGX has been the subject of several other reports. Wolfe Research raised shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price target for the company in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut argenx from a "hold" rating to a "sell" rating in a research report on Friday, January 17th. Robert W. Baird cut argenx from an "outperform" rating to a "neutral" rating and upped their price objective for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Evercore ISI raised their target price on shares of argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st. Finally, Oppenheimer reiterated an "outperform" rating and issued a $675.00 price target (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $662.83.

Remove Ads

argenx Stock Down 0.2 %

Shares of ARGX traded down $1.36 on Friday, hitting $621.25. The company's stock had a trading volume of 285,887 shares, compared to its average volume of 273,997. The firm's fifty day moving average price is $642.51 and its 200-day moving average price is $591.91. argenx has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The firm has a market capitalization of $37.75 billion, a price-to-earnings ratio of -705.97 and a beta of 0.58.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities analysts predict that argenx will post 3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenx

A number of large investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp raised its position in shares of argenx by 15.3% in the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock valued at $4,788,000 after buying an additional 1,170 shares in the last quarter. FMR LLC increased its position in argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. boosted its position in argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock valued at $1,311,000 after buying an additional 944 shares in the last quarter. Stephens Inc. AR bought a new position in shares of argenx in the 4th quarter valued at $310,000. Finally, Ritholtz Wealth Management grew its position in argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after acquiring an additional 414 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.